These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32977201)

  • 1. 1,3-Oxazine-2-one derived dual-targeted molecules against replicating and non-replicating forms of Mycobacterium tuberculosis.
    Velappan AB; Kesamsetty D; Datta D; Ma R; Hari N; Franzblau SG; Debnath J
    Eur J Med Chem; 2020 Dec; 208():112835. PubMed ID: 32977201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Aryl benzazole derived new class of anti-tubercular compounds: Endowed to eradicate mycobacterium tuberculosis in replicating and non-replicating forms.
    Velappan AB; Datta D; Ma R; Rana S; Ghosh KS; Hari N; Franzblau SG; Debnath J
    Bioorg Chem; 2020 Oct; 103():104170. PubMed ID: 32890990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
    Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
    Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of inhibitors targeting polyketide synthase 13 of Mycobacterium tuberculosis as antituberculosis drug leads.
    Wang X; Zhao W; Wang B; Ding W; Guo H; Zhao H; Meng J; Liu S; Lu Y; Liu Y; Zhang D
    Bioorg Chem; 2021 Sep; 114():105110. PubMed ID: 34175719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.
    Li W; Upadhyay A; Fontes FL; North EJ; Wang Y; Crans DC; Grzegorzewicz AE; Jones V; Franzblau SG; Lee RE; Crick DC; Jackson M
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6413-23. PubMed ID: 25136022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of
    Singh S; Khare G; Bahal RK; Ghosh PC; Tyagi AK
    Drug Des Devel Ther; 2018; 12():1065-1079. PubMed ID: 29750019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Small-Molecule Inhibitor of the
    Sukheja P; Kumar P; Mittal N; Li SG; Singleton E; Russo R; Perryman AL; Shrestha R; Awasthi D; Husain S; Soteropoulos P; Brukh R; Connell N; Freundlich JS; Alland D
    mBio; 2017 Feb; 8(1):. PubMed ID: 28196957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of new 2-aminothiophenes against Mycobacterium tuberculosis.
    Thanna S; Knudson SE; Grzegorzewicz A; Kapil S; Goins CM; Ronning DR; Jackson M; Slayden RA; Sucheck SJ
    Org Biomol Chem; 2016 Jul; 14(25):6119-6133. PubMed ID: 27251120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
    Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
    Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies.
    Sriram D; Yogeeswari P; Senthilkumar P; Naidu G; Bhat P
    J Enzyme Inhib Med Chem; 2010 Dec; 25(6):765-72. PubMed ID: 20569083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosis activity.
    Lin Y; Zhang H; Zhu N; Wang X; Han Y; Chen M; Jiang J; Si S
    Tuberculosis (Edinb); 2018 May; 110():79-85. PubMed ID: 29779778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A piperidinol-containing molecule is active against
    Dupont C; Chen Y; Xu Z; Roquet-Banères F; Blaise M; Witt AK; Dubar F; Biot C; Guérardel Y; Maurer FP; Chng SS; Kremer L
    J Biol Chem; 2019 Nov; 294(46):17512-17523. PubMed ID: 31562241
    [No Abstract]   [Full Text] [Related]  

  • 13. Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis.
    Lelovic N; Mitachi K; Yang J; Lemieux MR; Ji Y; Kurosu M
    J Antibiot (Tokyo); 2020 Nov; 73(11):780-789. PubMed ID: 32472054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
    Rani C; Mehra R; Sharma R; Chib R; Wazir P; Nargotra A; Khan IA
    Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of small-molecule inhibitors of fatty acyl-AMP and fatty acyl-CoA ligases in Mycobacterium tuberculosis.
    Baran M; Grimes KD; Sibbald PA; Fu P; Boshoff HIM; Wilson DJ; Aldrich CC
    Eur J Med Chem; 2020 Sep; 201():112408. PubMed ID: 32574901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
    Nizi MG; Desantis J; Nakatani Y; Massari S; Mazzarella MA; Shetye G; Sabatini S; Barreca ML; Manfroni G; Felicetti T; Rushton-Green R; Hards K; Latacz G; Satała G; Bojarski AJ; Cecchetti V; Kolář MH; Handzlik J; Cook GM; Franzblau SG; Tabarrini O
    Eur J Med Chem; 2020 Sep; 201():112420. PubMed ID: 32526553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Mycobacterium tuberculosis CtpF as a target for designing new antituberculous compounds.
    Santos P; Lopez-Vallejo F; Ramírez D; Caballero J; Mata Espinosa D; Hernández-Pando R; Soto CY
    Bioorg Med Chem; 2020 Feb; 28(3):115256. PubMed ID: 31879181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based drug design, synthesis and screening of MmaA1 inhibitors as novel anti-TB agents.
    Veeravarapu H; Malkhed V; Mustyala KK; Vadija R; Malikanti R; Vuruputuri U; Muthyala MKK
    Mol Divers; 2021 Feb; 25(1):351-366. PubMed ID: 32533514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the inhibitory activity of (aza)isoindolinone-type compounds: toward in vitro InhA action, Mycobacterium tuberculosis growth and mycolic acid biosynthesis.
    Chollet A; Stigliani JL; Pasca MR; Mori G; Lherbet C; Constant P; Quémard A; Bernadou J; Pratviel G; Bernardes-Génisson V
    Chem Biol Drug Des; 2016 Nov; 88(5):740-755. PubMed ID: 27301022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Effect of DFC-2 on Mycolic Acid Biosynthesis in
    Kim S; Seo H; Mahmud HA; Islam MI; Kim YS; Lyu J; Nam KW; Lee BE; Lee KI; Song HY
    J Microbiol Biotechnol; 2017 Nov; 27(11):1932-1941. PubMed ID: 28870005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.